ClinicalTrials.gg
CompletedNCT01436149Updated Jun 9, 2021Results posted

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate ) and Placebo in Major Depressive Disorder, sponsored by Shire. Completed at 85 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,262
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.

Enrollment
2nd of 24
1,262 · median 580
Started
2011
with 5 others
Phase 3
16 of 26
1 open now
Registered
15th of 26
by date

Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 16 in phase 3, and was the 15th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Depressive Disorder, Major by Takeda, or all of them as a file.
02

Study summary

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:

  • How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?
  • Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?
  • How much SPD489 should be given to patients with depression who are also taking an antidepressant?
  • How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able to provide written, personally signed, and dated to participate in the study.
  • Subject is between 18 and 65 years of age.
  • Subject has a primary diagnosis of non-psychotic MDD (single or recurrent).
  • Subject has a MADRS total score 24.
  • Subject who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test at the and agrees to comply with any applicable requirements of the protocol.
  • Subject is able to swallow a capsule.

Exclusion criteria

Exclusion Criteria:

  • Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.
  • Subject who has a lifetime history of treatment resistant depression.
  • Subject has a current co-morbid psychiatric disorder. Excluded are: any significant Axis II disorder (including borderline personality disorder), any bipolar disorder, any current or lifetime psychosis, post traumatic stress disorder, obsessive compulsive disorder, any pervasive development disorder, anorexia nervosa and bulimia nervosa.
  • Subject has been hospitalized (within the last 12 months) for their current MDD episode.
  • Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).
  • Subject has a first degree relative that has been diagnosed with bipolar I disorder.
  • Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder
  • Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.
  • Subject has a concurrent chronic or acute illness or unstable medical condition.
  • Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.
  • Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
  • Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.
  • Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  • Subject has glaucoma.
  • Subject has a history of moderate to severe hypertension.
  • Current use of any other medications (including over-the-counter [OTC], herbal or homeopathic preparations) that have central nervous system effects.
  • Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior.
  • The subject has a known or suspected intolerance, , or to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).
  • Subject has a positive urine drug result.
  • Subject has a (BMI) of \<18.5 or >40.
  • Subject is female and is pregnant or nursing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,262 participants (actual)

Study arms

  • Experimental
    Antidepressant + SPD489

    Drug: SPD489 (Lisdexamfetamine dimesylate )

  • Placebo comparator
    Antidepressant + Placebo

    Drug: Placebo

Interventions

  • Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks

    Also known as: Vyvanse

  • DrugPlacebo

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Time frame: 8 weeks

Secondary outcomes

  1. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks

    Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.

    Time frame: 8 weeks

  2. Percentage of Participants Achieving a 25% Response on the MADRS

    The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).

    Time frame: up to 8 weeks

  3. Percentage of Participants Achieving a 50% Response on the MADRS

    The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).

    Time frame: up to 8 weeks

  4. Percentage of Participants Achieving Remission on the MADRS

    MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).

    Time frame: up to 8 weeks

  5. Mean Change From Baseline Over Time in MADRS Total Score

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Time frame: Baseline and up to 8 weeks

  6. Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)

    The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \[low amount of symptom\]) to 3 (representing the least favorable response \[frequent/intense symptom\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.

    Time frame: up to 8 weeks

  7. Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)

    Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.

    Time frame: up to 8 weeks

  8. Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)

    The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.

    Time frame: up to 8 weeks

  9. Clinical Global Impressions - Global Improvement (CGI-I)

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: up to 8 weeks

  10. Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: up to 8 weeks

  11. Amphetamine Cessation Symptom Assessment (ACSA)

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: up to 8 weeks

07

Results

Posted Nov 19, 2014

Participant flow

Antidepressant Lead-in Phase
Participant flow — Antidepressant Lead-in Phase
MilestoneAntidepressant + Single-blind PlaceboAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489
Started126200
Completed89600
Not completed36600
Withdrew: Adverse event3900
Withdrew: Protocol violation2900
Withdrew: Withdrawal by subject6100
Withdrew: Lost to follow-up9600
Withdrew: Met bp or pulse withdrawal criteria2200
Withdrew: Other11900
Randomized Phase
Participant flow — Randomized Phase
MilestoneAntidepressant + Single-blind PlaceboAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489
Started492202202
Completed415164160
Not completed773842
Withdrew: Adverse event91011
Withdrew: Protocol violation450
Withdrew: Withdrawal by subject161010
Withdrew: Lost to follow-up3456
Withdrew: Lack of efficacy001
Withdrew: Met bp or pulse withdrawal criteria233
Withdrew: Other12511

Outcome measures

PrimaryMean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Time frame:
8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks-6.3 (-7.6 to -4.9)-6.1 (-7.5 to -4.8)
Statistical analysis
  • Antidepressant + Placebo vs Antidepressant + SPD489 · Mixed- effects Model for Repeat Measures · p = 0.883 · Difference in ls mean: 0.1 · 95% CI -1.7 to 2.0
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks

Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.

Time frame:
8 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks-4.3 (-5.3 to -3.3)-4.7 (-5.6 to -3.7)
Statistical analysis
  • Antidepressant + Placebo vs Antidepressant + SPD489 · Mixed- effects Model for Repeat Measures · p = 0.576 · Difference in ls mean: -0.4 · 95% CI -1.8 to 1.0
SecondaryPercentage of Participants Achieving a 25% Response on the MADRS

The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).

Time frame:
up to 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 25% Response on the MADRS
percentage of participantsAntidepressant + PlaceboAntidepressant + SPD489
Percentage of Participants Achieving a 25% Response on the MADRS65.074.5
SecondaryPercentage of Participants Achieving a 50% Response on the MADRS

The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).

Time frame:
up to 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 50% Response on the MADRS
percentage of participantsAntidepressant + PlaceboAntidepressant + SPD489
Percentage of Participants Achieving a 50% Response on the MADRS38.541.0
SecondaryPercentage of Participants Achieving Remission on the MADRS

MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).

Time frame:
up to 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission on the MADRS
percentage of participantsAntidepressant + PlaceboAntidepressant + SPD489
Percentage of Participants Achieving Remission on the MADRS22.518.5
SecondaryMean Change From Baseline Over Time in MADRS Total Score

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Time frame:
Baseline and up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline Over Time in MADRS Total Score
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Visit 9 (Week 9)-2.2 (-3.1 to -1.2)-3.4 (-4.3 to -2.4)
Visit 10 (Week 10)-3.8 (-4.9 to -2.7)-4.2 (-5.3 to -3.2)
Visit 11 (Week 11)-6.0 (-7.2 to -4.8)-5.4 (-6.6 to -4.2)
Visit 12 (Week 12)-6.2 (-7.4 to -5.0)-5.6 (-6.8 to -4.4)
Visit 13 (Week 14)-7.4 (-8.7 to -6.0)-7.3 (-8.6 to -6.0)
Visit 14 (Week 16)-6.3 (-7.6 to -4.9)-6.1 (-7.5 to -4.8)
SecondaryMean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)

The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \[low amount of symptom\]) to 3 (representing the least favorable response \[frequent/intense symptom\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.

Time frame:
up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)-2.6 (-3.2 to -1.9)-2.3 (-2.9 to -1.7)
SecondaryMean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)

Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.

Time frame:
up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Physical0.69 (-0.39 to 1.77)-0.81 (-1.89 to 0.28)
Mental5.59 (3.93 to 7.25)6.5 (4.84 to 8.16)
SecondaryMean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)

The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.

Time frame:
up to 8 weeks
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)7.2 (4.9 to 9.5)7.0 (4.7 to 9.3)
SecondaryClinical Global Impressions - Global Improvement (CGI-I)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
up to 8 weeks
Reported as:
Number · percentage of participants
Clinical Global Impressions - Global Improvement (CGI-I)
percentage of participantsAntidepressant + PlaceboAntidepressant + SPD489
Improved53.355.3
Not Improved46.244.7
Not Assessed0.50
SecondaryColumbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
up to 8 weeks
Reported as:
Number · percentage of participants
Columbia Suicide Severity Rating Scale (C-SSRS)
percentage of participantsAntidepressant + PlaceboAntidepressant + SPD489
≥1 postive suicidal ideation7.07.0
≥1 suicidal attempt0.50
SecondaryAmphetamine Cessation Symptom Assessment (ACSA)

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
up to 8 weeks
Reported as:
Mean · units on a scale
Amphetamine Cessation Symptom Assessment (ACSA)
units on a scaleAntidepressant + PlaceboAntidepressant + SPD489
Amphetamine Cessation Symptom Assessment (ACSA)15.1 ± 10.7114.7 ± 10.94

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Antidepressant + Placebo—5/201 (2.5%)54/201 (26.9%)
Antidepressant + SPD489—3/201 (1.5%)70/201 (34.8%)
Most frequent serious events
Most frequent serious events
EventAntidepressant + PlaceboAntidepressant + SPD489
VertigoEar and labyrinth disorders1/2010/201
AppendicitisInfections and infestations0/2011/201
Wound infectionInfections and infestations1/2010/201
Accidental overdoseInjury, poisoning and procedural complications0/2011/201
LacerationInjury, poisoning and procedural complications1/2010/201
SyncopeNervous system disorders1/2011/201
Major depressionPsychiatric disorders1/2010/201
Suicide attemptPsychiatric disorders1/2010/201
AppendicectomySurgical and medical procedures1/2010/201
Most frequent other events
Most frequent other events
EventAntidepressant + PlaceboAntidepressant + SPD489
HeadacheNervous system disorders21/20113/201
Dry mouthGastrointestinal disorders6/20119/201
InsomniaPsychiatric disorders15/20119/201
Decreased appetiteMetabolism and nutrition disorders8/20115/201
NauseaGastrointestinal disorders10/20113/201
NasopharyngitisInfections and infestations4/20111/201

Baseline characteristics

Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment (e.g., coming back for any visit, reporting of an adverse event \[AE\], or reporting the absence of AEs) after the Augmentation Baseline Visit (Visit 8).

Age, Continuous
Age, Continuous(Years)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489Total
Mean41.8 ± 12.0442.2 ± 12.3242 ± 12.17
Age, Customized
Age, Customized(Participants)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489Total
18-55 years173170343
56-65 years283159
Sex: Female, Male
Sex: Female, Male(Participants)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489Total
Female133129262
Male6872140
08

Study locations

85 sites
  • Birmingham Research Group
    Birmingham, Alabama 35216, United States
  • AV Institue, Inc.
    Carson, California 90746, United States
  • University of California, Irvine Child Development Center
    Irvine, California 92612, United States
  • South Coast Clinicals
    Norwalk, California 90650, United States
  • North County Clinical Research
    Oceanside, California 92056, United States
  • Pasadena Research Institute, LLC
    Pasadena, California 91106, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • Clinical Innovations, Inc.
    San Diego, California 92121, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • Geriatric and Adult Psychiatry, LLC
    Hamden, Connecticut 06518, United States
  • Middlexex Hospital Center for Behavioral Health
    Middletown, Connecticut 06457, United States
  • CNS Clinical Research Group
    Coral Springs, Florida 33067, United States
  • Emerald Coast Mood & Memory, PA
    Fort Walton Beach, Florida 32547, United States
  • Florida Clinical Research Center, LLC.
    Maitland, Florida 32751, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • American Medical Research, Inc.
    Oak Brook, Illinois 60523, United States
  • The Davis Clinic
    Indianapolis, Indiana 46260, United States
  • Northwest Indiana Center for Clinical Research
    Valparaiso, Indiana 46383, United States
  • MCM Clinical Research LLC
    Florence, Kentucky 41042, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • Potomac Grove Clinical Research Center
    Gaithersburg, Maryland 20877, United States
  • Office of Marc Hertzman, MD
    Rockville, Maryland 20852, United States
  • Adams Clinical Trials, LLC
    Watertown, Massachusetts 02472, United States
  • St. Charles Psychiatric Associates - Midwest Research Group
    Saint Charles, Missouri 63301, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • Fieve Clinical Research
    New York, New York 10168, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Triangle Neuropsychiatry
    Durham, North Carolina 27707, United States
  • Rcihard H. Weisler, MD, PA & Associates
    Raleigh, North Carolina 27809, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Lindner Center of HOPE
    Mason, Ohio 45040, United States
  • SP Research, PLLC
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Paramount Clinical Research
    Bridgeville, Pennsylvania 15107, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • CRI Worldwide LLC
    Philadelphia, Pennsylvania 19139, United States
  • University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Mood & Memory Research Institute
    East Providence, Rhode Island 02914, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • FutureSearch Clinical Trials, LP
    Austin, Texas 78731, United States
  • Ericksen Research and Development
    Clinton, Utah 84015, United States
  • Summit Research Network (Seattle) LLC
    Seattle, Washington 98104, United States
  • Dr. Alexander McIntyre Inc
    Penticton, British Columbia V2A 4M4, Canada
  • Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc.
    Vancouver, British Columbia V6Z 2L4, Canada
  • Aggarwal & Associates Ltd.
    Brampton, Ontario L6T 0G1, Canada
  • Depression, Mood Disorders and Schizophrenia Treatment Centre
    Burlington, Ontario L7R 4E2, Canada
  • Chatham-Kent Clinical Trials Research Center
    Chatham, Ontario N7M 5L9, Canada
  • Regional Mental Health Care
    London, Ontario N6A 4H1, Canada
  • Anxiety and Mood Disorder Center
    Mississauga, Ontario L5M 4N4, Canada
  • Medical Research Associates
    Mississauga, Ontario L5M 4N4, Canada
  • A.K. Karan Holdings
    Oakville, Ontario L6J0B2, Canada
  • International Sleep Clinic, West Parry Sound Health Centre
    Parry Sound, Ontario P2A 3A4, Canada
  • START Clinic for Mood and Anxiety Disorders
    Toronto, Ontario M4W 2N4, Canada
  • Univ Health Network, Toronto Western Hospital
    Toronto, Ontario M5T2S8, Canada
  • Sleep & Alertness Clinic (Sleep & Alertness Research, Inc.)
    Toronto, Ontario M6J 3S3, Canada
  • Manna Research
    Toronto, Ontario M9W 4L6, Canada
  • Windsor Regional Hospital-Tayfour Campus
    Windsor, Ontario N9C 3Z4, Canada
  • Pierre-Janet Hospital
    Gatineau, Quebec J8A1K7, Canada
  • l'Hopital Louis H. Lafontaine
    Montreal, Quebec H1N 3M5, Canada
  • Kells Medical Research Group Inc.
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Q&T Research Sherbrooke
    Sherbrooke, Quebec J1H 4J6, Canada
  • ALPHA Recherche Clinique
    Quebec, G3K 2P8, Canada
  • Poliklinika Neuron
    Zagreb, 10 000, Croatia
  • Psychiatric Clinic Vrapoe
    Zagreb, 10090, Croatia
  • Centro Regiomontano de Investigacion S.C. (CRI)
    Monterrey, Nuevo Leon 647-10, Mexico
  • Hospital Aranda de la Parra
    Leon Guanajuato, 37000, Mexico
  • Instituto de Infromacion e Investigación en Salud Mental (INFOSAME)
    Nuevo Leon, 64710, Mexico
  • Consultorio Especializado en Psiquiatria Infantil y Adolescentes
    San Luis Potosi, 78200, Mexico
  • B & B Investigaciones Medicas S.C.
    Sinaloa, 82126, Mexico
  • Dharma Institute & Research Center
    San Juan, 00907, Puerto Rico
  • INSPIRA Clinical Research
    San Juan, 00918, Puerto Rico
  • Hospital de la Santa Creo l Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitari de Bellvitge, Servicio de Psiquiatria
    Barcelona, 08907, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital Fundacion de Alcorcon
    Madrid, 28922, Spain
  • Hospital Universitario de Henares
    Madrid, Spain
  • Centro de Salud Mental Il la Corredoria
    Oviedo, 33011, Spain
  • Centro Salud Alamedilla Unidad de Salud Mental
    Salamanca, 37003, Spain
  • Complejo hospitalario de Zamora
    Zamora, 49021, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
09

References and documents

Publications

  • Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Affect Disord. 2016 Dec;206:151-160. doi: 10.1016/j.jad.2016.07.006. Epub 2016 Jul 5. PubMed 27474961 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Dec 2013, 25 months.

Results were first posted in Nov 2014, 10 months after primary completion. A results delay was requested in Aug 2014.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 25 months is close to that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 19, 2011
StartActual
Oct 27, 2011
Primary completionActual
Dec 23, 2013
CompletionActual
Dec 23, 2013
Results delay requested
Aug 20, 2014
Results first posted
Nov 19, 2014
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01436149
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Oct 27, 2011
Primary completion
Dec 23, 2013
Completion
Dec 23, 2013
Results posted
Nov 19, 2014
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion